Sequential changes in motor speech across a levodopa cycle in advanced Parkinson's disease

International Journal of Speech-Language Pathology

Volumn 12, Issue 5, 2010, Pages 405-413

  De Letter, Miet ^a,b   Van Borsel, John ^b   Boon, Paul ^a,b   De Bodt, Marc ^c   Dhooge, Ingeborg ^a,b   Santens, Patrick ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

dysarthria; levodopa; medication cycle; motor speech; Parkinson's disease; pharmacology

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; PARKINSON DISEASE; SPEECH; SPEECH DISORDER;

ADULT; AGED; ANTIPARKINSON AGENTS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; SPEECH; SPEECH DISORDERS;

EID: 77956069082     PISSN: 17549515     EISSN: 17549507     Source Type: Journal    
DOI: 10.3109/17549507.2010.491556     Document Type: Article

References (43)

1. Adelman, J. U., Hoel, R. L., & Lassman, M. E. (1970). The effect of L-DOPA treatment on speech of patients with Parkinson's disease. Neurology, 20, 410-411.
2. Braak, H., Del Tredici, K., Rub, U., de Vos, R. A., Jansen Steur, E. N., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiological Aging, 24, 197-211.
3. Cahill, L. M., Murdoch, B. E., Theodoros, D. G., Triggs, E. J., Charles, B. G., & Yao, A. A. (1998). Effect of oral levodopa treatment on articulatory function in Parkinson's disease: Preliminary results. Motor Control, 2, 161-172.
4. Critchley, E. M. (1981). Speech disorders of Parkinsonism: A review. Journal of Neurology, Neurosurgery and Psychiatry, 44, 751-758.
5. De Letter, M., Santens, P., & Van Borsel, J. (2003). The effects of levodopa on tongue strength and endurance in patients with Parkinson's disease. Acta Neurologica Belgica, 103, 35-38.
6. De Letter, M., Santens, P., & Van Borsel, J. (2005). The effects of levodopa on word intelligibility in Parkinson's disease. Journal of Communication Disorders, 38, 187-196.
7. De Letter, M., Santens, P., De Bodt, M., Boon, P., & Van Borsel, J. (2006). Levodopa-induced alterations in speech rate in advanced Parkinson's disease. Acta Neurologica Belgica, 106, 19-26.
8. De Letter, M., Santens, P., De Bodt, M., Van Maele, G., Van Borsel, J., & Boon, P. (2007a). The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease. Clinical Neurology and Neurosurgery, 109, 495-500.
9. De Letter, M., Santens, P., Estercam, I., Van Maele, G., De Bodt, M., Boon, P., et al. (2007b). Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners. Clinical Linguistics and Phonetics, 21, 783-791.
10. Defer, G. L., Widner, H., Marie, R. M., Remy, P., & Levivier, M. (1999). Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Movement Disorders, 14, 572-584.
11. Dykstra, A. D., Hakel,M. E., & Adams, S. G. (2007). Application of the ICF in reduced speech intelligibility in dysarthria. Seminars in Speech and Language, 28, 301-311.
12. Enderby, P. (1980). Frenchay Dysarthria Assessment. International Journal of Language and Communication Disorders, 15, 165-173.
13. Fahn, S., Elton, R. L. & Members of the UPDRS Development Committee (1987). Unified Parkinson's disease rating scale. In S. Fahn, C. D. Marsden, D. Calne, M. Goldstein (Eds.), Recent developments in Parkinson's disease 2 (pp. 153-163). Florham Park, NJ: Macmillan Healthcare Information.
14. Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Minimental state. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198.
15. Gardner, W. N., Langdon, N., & Parkes, J. D. (1987). Breathing in Parkinson's disease. Advances in Neurology, 45, 271-274.
16. Gentil, M., Tournier, C. L., Pollak, P., & Benabid, A. L. (1999). Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease. European Neurology, 42, 136-140.
17. Goberman, A., & McMillan, J. (2005). Relative speech timing in Parkinson's disease. Continuing Issues in Communication Science and Disorders, 2005, 22-29.
18. Goberman, A. M., & Coelho, C. (2002). Acoustic analysis of Parkinsonian speech II: L-Dopa related fluctuations and methodological issues. NeuroRehabilitation, 17, 247-254.
19. Goberman, A. M., Coelho, C., & Robb, M. (2002). Phonatory characteristics of Parkinsonian speech before and after morning medication: The ON and OFF states. Journal of Communication Disorders, 35, 217-239.
20. Hage, R., & Jurgens, U. (2006). On the role of the pontine brainstem in vocal pattern generation: A telemetric single-unit recording study in the squirrel monkey. The Journal of Neuroscience, 26, 7105-7115.
21. Hage, S. R., Jurgens, U., & Ehret, G. (2006). Audio-vocal interaction in the pontine brainstem during self-initiated vocalization in the squirrel monkey. European Journal of Neuroscience, 23, 3297-3308.
22. Harel, B., Cannizzaro, M., & Snyder, P. J. (2004). Variability in fundamental frequency during speech in prodromal and incipient Parkinson's disease: A longitudinal case study. Brain and Cognition, 56, 24-29.
23. Ho, A. K., Bradshaw, J. L., & Iansek, R. (2008). For better or worse: The effect of levodopa on speech in Parkinson's disease. Movement Disorders, 15, 574-580.
24. Hoehn, M. M., & Yahr, M. D. (1998). Parkinsonism: Onset, progression and mortality. Neurology, 50, 318-333.
25. Kleinow, J., Smith, A., & Ramig, L. O. (2001). Speech motor stability in IPD: Effects of rate and loudness manipulations. Journal of Speech, Language, and Hearing Research, 44, 1041-1051.
26. Kompoliti, K., Wang, Q. E., Goetz, C. G., Leurgans, S., &Raman, R. (2000). Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology, 25, 458-462.
27. Limousin, P., Krack, P., Pollak, P., Benazzouz, A., Ardouin, C., Hoffmann, D., et al. (1998). Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. New England Journal of Medicine, 15, 1105-1111.
28. Louis, E. D., Winfield, L., Fahn, S., & Ford, B. (2001). Speech dysfluency exacerbated by levodopa in Parkinson's disease. Movement Disorders, 16, 562-565.
29. MacKay-Lyons, K. (1999). Variability in spatiotemporal gait characteristics over the course of the L-dopa cycle in people with advanced Parkinson disease. Physical Therapy, 78, 1083-1094.
30. Metter, E. J., & Hanson, W. R. (1986). Clinical and acoustical variability in hypokinetic dysarthria. Journal of Communication Disorders, 19, 347-366.
31. Murdoch, B. E., Chenery, H. J., Bowler, S., & Ingram, J. C. (1989). Respiratory function in Parkinson's subjects exhibiting a perceptible speech deficit: A kinematic and spirometric analysis. Journal of Speech and Hearing Disorders, 54, 610-626.
32. Nakano, K. K., Zubick, H., & Tyler, H. R. (1973). Speech defects of Parkinsonian patients: Effects of levodopa therapy on speech intelligibility. Neurology, 23, 865-870.
33. Olanow, C. W., Gauger, L. L., & Cedarbaum, J. M. (1991). Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Annals of Neurology, 29, 556-559.
34. Poluha, P. C., Teulings, H. L., & Brookshire, R. H. (1998). Handwriting and speech changes across the levodopa cycle in Parkinson's disease. Acta Psychologica, 100, 71-84.
35. Rice, J. E., Antic, R., & Thompson, P. D. (2002). Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease. Movement Disorders, 17, 524-527.
36. Sanabria, J., Ruiz, P. G., Gutierrez, R., Marquez, F., Escobar, P., Gentil, M., et al. (2001). The effect of levodopa on vocal function in Parkinson's disease. Clinical Neuropharmacology, 24, 99-102.
37. Santens, P., De Letter, M., Van Borsel, J., De Reuck, J., &Caemaert, J. (2003). Lateralized effects of subthalamic nucleus stimulation on different aspects of speech in Parkinson's disease. Brain and Language, 87, 253-258.
38. Schulz, G. M., Varga, M., Jeffires, K., Ludlow, C. L., & Braun, A. R. (2005). Functional neuroanatomy of human vocalization: An H215O PET study. Cerebral Cortex, 15, 1835-1847.
39. Solomon, N. P., & Hixon, T. J. (1993). Speech breathing in Parkinson's disease. Journal of Speech and Hearing Research, 36, 294-310.
40. Solomon, N. P., Robin, D. A., & Luschei, E. S. (2000). Strength, endurance and stability of the tongue and hand in Parkinson disease. Journal of Speech, Language and Hearing Research, 43, 256-267.
41. Steiger, M. J., Thompson, P. D., & Marsden, C. D. (1996). Disordered axial movement in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 61, 645-648.
42. Vercueil, L., Linard, J., Wuyam, B., Pollak, P., & Benchetrit, G. (1999). Breathing pattern in patients with Parkinson's disease. Respiratory Physiology, 118, 163-172.
43. Wolfe, V. I., Garvin, J. S., Bacon, M., & Waldrop, W. (1975). Speech changes in Parkinson's disease during treatment with L-dopa. Journal of Communication Disorders, 8, 271-279.